Merck & Co., Inc. (MRK)
Merck: Now A Single-Digit P/E With Double-Digit EPS Growth, Technical Support
The Health Care sector outperformed the S&P 500 in 2025, with XLV returning -1.5% YTD compared to SPY's -10% decline. Despite mixed performance, Merck's stock has dropped 37% since mid-2024, but I maintain a buy rating due to long-term support and potential growth drivers. Merck's Q4 results beat expectations, but concerns over Gardasil and Keytruda's patent expirations have weighed on the stock.
Merck & Co.: Pipeline Resilience To Unlock Value
I initiate coverage on Merck & Co., Inc. with a Strong Buy rating and a $139 price target, driven by resilient execution and robust product depth. Merck is growing pharma sales and expanding margins, led by strong KEYTRUDA performance and cost discipline. New product launches like WINREVAIR are exceeding expectations and offsetting pipeline risk.
Ahead of Merck (MRK) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Beyond analysts' top -and-bottom-line estimates for Merck (MRK), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2025.
Merck (MRK) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Merck (MRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock
Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Merck (MRK) Stock Drops Despite Market Gains: Important Facts to Note
The latest trading day saw Merck (MRK) settling at $79.17, representing a -0.01% change from its previous close.
Wall Street Analysts Think Merck (MRK) Is a Good Investment: Is It?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Bernstein's Courtney Breen: Merck, Novo Nordisk, others at high risk from tariffs
Courtney Breen, Bernstein senior analyst, joins CNBC's 'Money Movers' to discuss how to draw the line between tariff risks and company financials in pharmaceuticals, which companies are most at risk, and more.
Why the Market Dipped But Merck (MRK) Gained Today
In the closing of the recent trading day, Merck (MRK) stood at $89.23, denoting a +1.86% change from the preceding trading day.
FDA Accepts Merck's Filing for Subcutaneous Version of Keytruda
The filing is based on late-stage data, which shows that treatment with the subcutaneous version of MRK's Keytruda is at least as effective as the IV version.
Merck Gets EC Nod for 21-Valent Pneumococcal Jab Capvaxive
The European Commission approves MRK's pneumococcal 21-valent conjugate vaccine, Capvaxive, for pneumococcal vaccination in adults.
Merck plans US to launch subcutaneous version of Keytruda on October 1
Merck & Co said on Thursday that it plans to launch a subcutaneously injected version of its blockbuster cancer immunotherapy Keytruda in the U.S. on October 1, and expects to hit peak adoption rates of the new version within two years.
